| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $759K | -49.9% | — |
| Cost of Revenue | $806K | -41.8% | — |
| Gross Profit | -$47K | -135.9% | — |
| R&D Expense | $10.1M | -0.0% | +7.1% |
| SG&A Expense | $5.2M | -13.1% | -8.2% |
| Operating Income | -$15.3M | +2.1% | -7.9% |
| Net Income | -$13.3M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $17.9M | +14.7% | -36.3% |
| Short-term Investments | $87.1M | -6.3% | -29.1% |
| Accounts Receivable | $726K | -39.1% | -42.2% |
| Current Assets | $110.0M | -4.0% | -31.9% |
| Total Assets | $216.2M | -5.7% | -20.6% |
| Current Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$34.7M | — | — |
| Capital Expenditures | $22.0M | — | — |
| Investing Cash Flow | $43.9M | — | — |
| Financing Cash Flow | -$588K | — | — |
| Free Cash Flow | -$56.7M | — | — |
| -19.1% |
| EPS (Basic) | -$0.08 | +0.0% | -33.3% |
| EPS (Diluted) | -$0.08 | +0.0% | -33.3% |
| $10.0M |
| -2.7% |
| +9.0% |
| Total Liabilities | $12.4M | -7.2% | -15.0% |
| Stockholders' Equity | $203.9M | -5.6% | -20.9% |